Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2023* 08:00 EST Earnings Call Q4 2022 -- -- --
02/24/2023* -- Results Q4 2022 -- 4.79 --
11/03/2022 08:00 EST Earnings Call Q3 2022 -- -- --
11/03/2022 -- Results Q3 2022 2.53 3.11 -18.61%
08/03/2022 08:00 EST Earnings Call Q2 2022 -- -- --
08/03/2022 -- Results Q2 2022 5.24 4.49 16.64%
05/04/2022 -- Results Q1 2022 8.58 5.62 52.59%
05/04/2022 08:00 EST Earnings Call Q1 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/24/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since 23.63%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
URL https://www.modernatx.com
Investor Relations URL https://investors.modernatx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Blend
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
28.09%
434.1%
143.1%
-28.20%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
1.16%
15.32%
24.40%
-5.14%
16.21%
10.85%
11.45%
7.31%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
47.20%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-11.00%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
21.36%
As of December 02, 2022.

Profile

Edit
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
URL https://www.modernatx.com
Investor Relations URL https://investors.modernatx.com/
HQ State/Province Massachusetts
Sector Healthcare
Industry Biotechnology
Equity Style Large Cap/Blend
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
IBB 473.48M USD 5.45%
FBT 58.71M USD 4.11%
VWIGX 1.489B USD 3.88%
COWZ 236.60M USD 2.36%
PFPWX 104.87M USD 2.32%
TDB875 24.98M USD 1.42%
THISX 194.54M USD 1.41%
XBI 108.09M USD 1.40%
JLCVX 60.94M USD 1.37%
VWUSX 432.83M USD 1.32%
XLV 485.32M USD 1.15%
RSP 83.04M USD 0.25%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter MRNA Tweets